Glenmark Forges Global Partnership to Advance Lung Cancer Treatment

Glenmark Pharmaceuticals has partnered with China's Hansoh Pharma to commercialize Aumolertinib, a drug for non-small cell lung cancer, across multiple global markets. The agreement grants Glenmark exclusive development and commercialization rights in specified regions, while Hansoh Pharma will receive milestone payments and royalties.

Glenmark Pharmaceuticals announced a pivotal collaboration with China's Hansoh Pharma to bring a promising lung cancer drug to diverse international markets.

The partnership centers on Aumolertinib, a cutting-edge epidermal growth factor receptor tyrosine kinase inhibitor, aimed at treating non-small cell lung cancer. Glenmark Specialty SA, a subsidiary, will lead development and commercialization efforts in designated regions, including the Middle East, Africa, and Southeast Asia.

Hansoh Pharma will benefit from an initial financial infusion and potentially significant milestone and royalty payments. Glenmark's Chairman, Glenn Saldanha, emphasized the strategic expansion of their innovative cancer treatment portfolio through this collaboration.

(With inputs from agencies.)